We also wanted to determine if CDC25B levels reflect gemcitabine sensitivity since gemcitabine-based combination chemotherapy is a current standard of care for pancreatic cancer, and we have reported that a BETi + gemcitabine is synergistic in vitro in parent pancreatic cancer cell lines[29]. Here, CDC25B is linked to pancreatic neoplasm.